Citrate Anticoagulation vs. Heparin-Coated Dialyzers

Phase 3

Completed

• Conditions: Dialysis

• Registration Number: NCT00395824
• Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Brief Summary

Hemodialysis causes contact activation of the coagulation pathway (1). For this reason, unfractionated or low molecular weight heparins are administered in daily practice to prevent thrombosis of the dialyzer and blood circuit, but the dose commonly used causes systemic anticoagulation. This can cause serious complications in patients with high risk of bleeding. Regional and low-dose heparinization, use of prostacycline, regional citrate anticoagulation (RCA), and high-flow-rate hemodialysis without anticoagulation have been shown to reduce bleeding complications. Each of these methods, however, is characterized by its own technical difficulties, limitations, or complications.

The present study aimed to compare the efficacy and safety of heparin-coated polyacrylonitrile membranes (AN69ST) and regional citrate anticoagulation in hemodialysis patients at risk of bleeding

Detailed Description

1. Open label single centre prospective randomized trial including 33 patients aged over 18 years with chronic kidney disease stage 5 requiring intermittent hemodialysis at the University Hospital Leuven and at risk of bleeding. Exclusion criteria were: any haemostatic disorder favouring either bleeding or clotting, anti-vitamin K or heparin treatment, heparin induced thrombocytopenia and haemodynamic instability. Written informed consent before enrolment.

2. Random allocation (by sealed enveloppe) to RCA with a calcium free dialysate (RCA-Ca0), RCA with a calcium containing dialysate (RCA-Ca1,5) or to anticoagulant-free hemodiaysis with a heparin-coated polyacrylonitrile membrane (Nephral 300ST®).

3. At the end of each dialysis session, arterial and venous drip chambers and the filter will be inspected for visible signs of coagulation. Corresponding to the standard care at our dialysis unit, a semi-quantitative score with a range from 0 (no signs of clotting) to 4 (complete occlusion) will be used for evaluation of the dialyzer. By definition, the drip chamber will be considered clotted when a thrombus was visible after the rinse back procedure. A fibrin ring against the wall of the drip chamber will be considered normal.

4. Blood samples for assessment of prothrombin fragment F1+2 and d-dimers will be collected from the inlet blood catheter prior to hemodialysis initiation and during hemodialysis at T15, T120 and T238.

Study Timeline

• Study Start: 2005-01
• Study Completion: 2005-09
• Status Verified: 2006-11
• Study First Submitted: 2006-11-02
• Study First Submitted QC: 2006-11-02
• Last Update Submitted: 2006-11-02
• Study First Posted: 2006-11-03
• Last Update Posted: 2006-11-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• aged over 18 years
• chronic kidney disease stage 5 requiring intermittent hemodialysis
• at risk of bleeding
• written informed consent

Exclusion Criteria

• any haemostatic disorder favouring either bleeding or clotting
• anti-vitamin K or heparin treatment
• heparin induced thrombocytopenia
• haemodynamic instability

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
anticoagulation efficacy as evaluated by clotting score of dialyser
anticoagulation efficacy as evaluated by occurrence of major and minor clotting events
anticoagulation efficacy as evaluated by instantaneous blood clearances

Secondary Outcome Measures

Name	Time	Method
anticoagulation efficay as evaluated by time course of coagulation parameters

Trial Locations

Locations (1)

University Hopsital Leuven; 🇧🇪 Leuven, Belgium